 BALTIMORE--BUSINESS WIRE--MyMD Pharmaceuticals, Inc. Nasdaq: MYMD MyMD or the Company, a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced data from a comparative study conducted by Eurofins Discovery showing commonality between its lead clinical compound MYMD-1 and three FDA-approved JAK inhibitor drugs for the treatment of autoimmune and inflammatory diseases. Janus Kinases JAKs are en 